While I’m under shelter-in-place here in Bklyn., I’m also sick most likely with the common cold (at least, I’m hoping that’s what it is). Even if I wanted to, I couldn’t be tested to see if it was COVID-19 because those tests are only avialbe to those seriously ill.
I’m self-medicating with my homemade chicken soup and Vicks Vapo Rub.
There are different components to completing the test. There maybe enough testing kits for the labs, but there is definitely a shortage of the nasopharyngeal swabs that are needed to collect the specimens. My hospital only tests people sick enough to be admitted. We don’t have enough swabs to test everyone, even if they have symptoms.
And that’s just the lab costs. Add in doctor visit charges and etc, you’re going to to be a lot higher.
Hi Technologies, a Brazilian healthtech that produces portable labs, is currently working at full speed to produce quick tests for Covid-19 that returns results in 15 minutes.
Earlier this month, the company announced the consumer price for the test would be 130 reais ($25), but Figueredo noted the company has since managed to negotiate with suppliers to further reduce the final price, yet to be announced.
And:
In about three months’ time, U.K.-based Mologic Ltd., in collaboration with Senegalese research foundation Institut Pasteur de Dakar, could shorten that wait to 10 minutes with a test that will help a continent with the world’s most fragile healthcare system cope with the pandemic.
That’s where Mologic comes in. Using technology from home pregnancy and malaria tests, its saliva and finger-prick kit could be ready for sale from June for less than $1 apiece.
Set up in 2007, Bioeasy is mainly engaged in food and drug safety as well as clinical diagnosis. It is at the moment seeking to raise CNY213 million (USD30.1 million) in an initial public offering on the Shenzhen stock exchange’s Nasdaq-style ChiNext board. The firm had net profit of CNY74 million on revenue of CNY205 million in 2018, according to its IPO prospectus submitted last July.
There was a flurry of quick tests developed on the fly and used in Wuhan. It looks like the big players will be licensing in the technology from Europe and elsewhere in Asia.
Do you know for a fact that that is true in Texas? We have two drive through testing sites in Dallas. We have a limited capacity for testing because of the federal government.
My daughter works with first to third graders in Turku, Finland, and they kept the day cares and young children’s care and school open until last week. Part of the reason was to make sure the necessary workers could go to work. Both the Swedish model and the Finnish model show the most likely infected is a 10-year-old, so there was a very big effort to lock down the 70 and overs in both countries and keep them away from children and their parents. A lot of FaceTime with the grandkids. Sweden, unlike any of the other Nordics, has gone its own way on this. Norway is particularly strict. What is different with Sweden is that it did get its lead epidemiologist on the ground in Wuhan for more than a month very early in the outbreak, so they also are using a different model which seeks a very flattened curve that still allows for enough infection that there is some herd immunity, a very painful strategy already that could go very wrong, but could also yield benefits at the second wave. Much crazier and dangerous was the low-brow, non-data-driven approach cobbed together by the UK’s new Tory government. Now that was nuts!
Frankly, it’s not even just them. No other administration before us envisioned this sort of thing, yet still they did nothing to prepare us for it. They left us empty stockpiles and no plans - zero plans - nothing at all to help!
Sweden has had a number of deaths due the virus, then you add in open borders, and you’re watching Typhoid Mary in the shape of a country adding to the spread
By Saturday, Norway, population 5.3 million, had more than 3,770 coronavirus cases and 19 deaths; Denmark, population 5.6 million, reported 2,200 cases and 52 deaths; Sweden, with 10.12 million people, recorded more than 3,060 cases and 105 deaths.